AML Pathfinder

---

ONLINEAML Pathfinder

Friday, July 10, 2020, 12:00 AM - Saturday, July 10, 2021, 11:59 PM


AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

AML Pathfinder is a 1 hour internet enduring material designed to provide practical guidance regarding incorporating new treatment options integrated with clinical information, data, and guidelines.  

1. Review and highlight treatment strategies based on the most current clinical practice guidelines, new approvals and approaches for patients with newly diagnosed acute myeloid leukemia (AML).
2. Discuss strategies for implementing recent drug approvals and review evidence-based regimens for specific patients with relapsed or refractory AML, including management of toxicities.
3. Evaluate the prognostic implications of molecular and cytogenic features of AML and discuss applying this information into new treatment strategies in mutation-harboring patients

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Supported by educational grants from AbbVie Inc. and Astellas Pharma Inc.